Multi-institutional phase I trials of anticancer agents

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 1926-1931

  Dowlati, Afshin ^a   Manda, Sudhir ^a   Gibbons, Joseph ^a   Remick, Scot C ^a   Patrick, Lauren ^a   Fu, Pingfu ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CENTER; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MYELOMA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; BIOASSAY; ECONOMICS; METHODOLOGY; MULTICENTER STUDY; NEOPLASM;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; ENDPOINT DETERMINATION; HUMANS; MAXIMUM TOLERATED DOSE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS;

EID: 42949135952     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.3793     Document Type: Article

References (5)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000
2. Adjei AA: What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol 24:4054-4055, 2006
3. Dowlati A, Robertson K, Radovotyicivh T, et al: Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the anti-angiogenic agent SU5416. Clin Cancer Res 11:7938-7944, 2005
4. Dowlati A, Haaga J, Remick SC, et al: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7:2971-2976, 2001
5. Tolcher AW, Takimoto CH, Rowinsky EK: The multifunctional, multi-institutional, and sometimes even global phase I study: A better life for phase I evaluations or just "living large"? J Clin Oncol 20:4276-4278, 2002